Related Experiment Videos
Early rheumatoid arthritis. Future treatment
1Department of Rheumatology, Leiden University Hospital, The Netherlands.
Bailliere'S Clinical Rheumatology
|February 1, 1997
Summary
Biotechnology offers new rheumatoid arthritis (RA) treatments. While early immune-based therapies show limited success, monoclonal antibodies targeting TNF alpha are promising for autoimmune response management.
Area of Science:
- Immunology
- Biotechnology
- Rheumatology
Background:
- Rheumatoid arthritis (RA) pathophysiology is increasingly understood.
- Biotechnological advances are expected to yield targeted RA therapies.
Purpose of the Study:
- Review the use of biological agents for rheumatoid arthritis (RA) treatment.
- Discuss advancements in immune-based therapies for RA.
Main Methods:
- Review of preclinical and clinical studies on biological agents for RA.
- Analysis of data from animal models and human trials.
Main Results:
- Vaccine strategies in animal models showed promise but lacked clinical efficacy in preliminary human studies.
- Monoclonal antibodies against leukocyte surface antigens had initial promise, not sustained in controlled trials.
- Monoclonal antibodies targeting TNF alpha demonstrated encouraging results in placebo-controlled studies.
Conclusions:
- Biological agents are evolving as targeted therapies for RA.
- While development is ongoing, advancements suggest more effective treatments for autoimmune responses in RA are likely.